Materials and Methods This descriptive observational study was carried out in a General Hospital, over a period of 24 months between January 2010 and December 2011. All patients diagnosed with AMD who received at least one dose of intravitreal ranibizumab were included.

Results 77 patients were included in the study, with a total of 82 eyes treated. This involved the administration of 259 injections of intravitreal ranibizumab. Each dose cost €549.75. In total, the consumption of intravitreal ranibizumab to treat the AMD during the period of study carried an expense of €142,385.25.

Considering that the unit cost of intravitreal bevacizumab is €4.08, the administration of this drug instead of ranibizumab would have cost €1,056.72.

Conclusions Ranibizumab is 135 times more expensive than bevacizumab. In this group of patients, the use of bevacizumab would have reduced costs by approximately €141,000.

No conflict of interest.

Abstract OHP-018 Table 1 Adjusted complication rate (%)

<table>
<thead>
<tr>
<th>Complications</th>
<th>Infectious</th>
<th>Mechanical</th>
<th>Obstructive/thrombosis</th>
<th>Absence of complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVP</td>
<td>0.41</td>
<td>0.16</td>
<td>0.31</td>
<td>99.1</td>
</tr>
<tr>
<td>PICC</td>
<td>0.76</td>
<td>9.28</td>
<td>0.76</td>
<td>82.3</td>
</tr>
</tbody>
</table>

No conflict of interest.

OHP-019 DAY-1 CALL IN AN ONCOLOGY DAY UNIT: WHAT IMPROVEMENTS?

doi:10.1136/ejhpharm-2013-000276.393

L Tran, M Jardin, M Cherifi, Y Bezie, G Deplanque. ‘Groupe Hospitalier Paris Saint Joseph, 75014 Paris, France

Background The preparation in advance of anticancer drugs can decrease the waiting time of patients in oncology day units.

Purpose To establish a system of phoning patients before their session (D-1 call) to check their availability. A year after its deployment, we evaluated the impact of this plan.

Materials and Methods The oncologist and a nurse call patients one day before their appointment. The prescriptions are validated when the patient’s condition permits it in the light of the patient’s biological assessment, done in an outside medical analysis laboratory, and an interview using a standardised questionnaire. After pharmaceutical validation, anticancer drugs are prepared in the afternoon for the next day. Indicators of routine monitoring were defined.

Results A median of 13 patients with 23 planned day-hospital appointments were called the day before their appointment. An oncologist validated the treatment of 45% of the patients on D-1 and 95% of the cancer treatments were delivered on D1 before 9:00 am. The total time the patients spent in the unit was reduced from 273 minutes to 242 minutes after our plan was adopted. The average time between the end of the medical consultation and the start of the treatment went down from 79 minutes before the D-1 call to 52 minutes. In addition, 2/3 of patients received the treatment only 30 minutes after seeing their doctor. Finally, fewer than 2% of anticipated preparations were not administered.

Conclusions The D-1 call requires significant effort, but it enables us to improve the organisation of care in the oncology day unit and the preparation of the anticancer drugs by the pharmacy’s production unit. The workload is more even throughout the day and is not stressful for the staff. All of this contributes to making the system safer. We are hoping to extend the D-1 call to the oncology week unit and evaluate patient satisfaction.

No conflict of interest.

OHP-020 DE-ESCALATION STRATEGY OF EMPirical ANTIBiotic TREATMENT WITH CARBAPENEMS

doi:10.1136/ejhpharm-2013-000276.394

S Sadyrbaeva, P Amarte Padial, N El-Fahimi, E Puerta García, C Caparros Romero, A Madrid Parede, MA Calleja Hernández, Virgen de las Nieves University Hospital, Hospital Farmacy, Granada, Spain

Background Therapeutic de-escalation enables us to improve the effectiveness of empirical antimicrobial therapy and avoids the development of resistance.

Purpose To analyse the preliminary results of a pilot project of pharmacy interventions to achieve de-escalation of treatment with carbapenems, within a programme of optimisation of antibiotics use.

Materials and Methods Prospective study of pharmacy interventions aimed at de-escalation in patients starting treatment with carbapenems, over three months (from March to June 2012) in a